In this video, Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the management of prefibrotic myelofibrosis (MF), commenting on recent updates in the classification and prognostication of this disease. Dr Bose also discusses the importance of early intervention, and the potential role of agents including ruxolitinib and ropeginterferon alfa-2b in the treatment of prefibrotic MF. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.